LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $7.23B
- P/E (TTM)
- –
- Dividend yield
- –
Legend Biotech Corp revenue by segment
By business segment
By product or service
By region
| Revenue | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q4 22 | Q4 21 | Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | – | $18.00K | $19.96M | $90.00K | $96.00K | $30.00K | $53.00K | $141.00K | – | – | – | – | – | – |
| United States | – | $10.48M | $15.39M | $9.35M | $18.41M | $17.35M | $93.22M | $15.37M | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Legend Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.